Efficacy of a new ready-to-use PCV2 and Mycoplasma hyopneumoniae vaccine under field conditions

Coinfection of porcine circovirus type 2 (PCV2) with <i>Mycoplasma hyopneumoniae</i> (<i>M. hyo</i>) causes major worldwide economic losses within the swine industry. This study aimed to assess the safety and efficacy of a single dose of a bivalent vaccine containing PCV2d and <i>M. hyo</i> antigen (Cirbloc^® M Hyo) under field conditions. Two studies were performed under the GCP (Good Clinical Practice) requirements on farrow-to-finish farms in Hungary and Cyprus. On both farms, the presence of both PCV2 and <i>M. hyo</i> infection was demonstrated. For both studies, safety parameters were observed and measured from inclusion at 21 (±3) days of age until 14 days after vaccination. Efficacy parameters were observed and measured from inclusion until slaughter. Administration of the vaccine was safe in both studies, as no general, immediate, or local reactions were observed. The efficacy of the vaccine was confirmed in both studies as the following parameters were significantly reduced in the vaccinated groups compared to the control groups: viraemia, faecal shedding, viral load in lungs and in all collected lymphoid tissues, <i>M. hyo</i>-specific lung lesions, and average daily body weight gain. These results collectively support the vaccine's potential as an effective tool for disease control.